Hong Kong Healthcare Services Stock News

Why Great Wall Motor’s latest production and sales update matters for investors Great Wall Motor (SEHK:2333) has released unaudited production and sales figures for May 2026, providing a fresh snapshot of how the business is running so far this year. For May, production was 110,423 units compared with 101,888 units a year earlier, while sales were 100,399 units versus 102,231 units in the same month last year, highlighting a mixed monthly picture. Looking at the year to date, production...

HBM Holdings (SEHK:2142) is back in focus after China’s National Medical Products Administration accepted its investigational new drug filing for HBM7004, a bispecific antibody for advanced solid tumors, following earlier U.S. FDA clearance. See our latest analysis for HBM Holdings. Despite the positive regulatory news, the stock’s recent momentum has cooled, with a 30 day share price return down 21.58% and the year to date share price return down 16.97%. This comes even as the 1 year total...

Sunny Optical Technology (Group) (SEHK:2382) has been removed from the Hang Seng China Enterprises Index. This change can affect index-tracking flows and how some institutional investors view the stock. See our latest analysis for Sunny Optical Technology (Group). The index removal comes after a sharp 12.8% decline in the 7 day share price return, even though the 30 day and 90 day share price returns of 8.74% and 26.86% point to recovering momentum from a HK$71.55 base. This compares with a 1...

BYD Electronic (International) Company Limited announced at its 9 June 2026 AGM that it approved a 2025 final dividend of RMB 0.156 per share and confirmed board changes, including the retirement of two independent non-executive directors. The appointment of industry veteran Ms. Rong Xiu-li and accounting expert Professor Mr. Cao Yu-shan to lead key board committees materially reshapes the company’s governance profile. We will now examine how these refreshed independent appointments,...

If you are trying to figure out whether WuXi Biologics (Cayman) is attractively priced or not, a useful starting point is to separate short term share price noise from the company’s underlying value. The stock last closed at HK$31.08. The share price is up 11.0% over the past year but down 5.1% over the past week, 8.2% over the past month and 34.5% over three years, while the five year return is down 76.5%. Recent headlines around WuXi Biologics (Cayman) have focused on broader sector...

Asia-express Logistics Holdings Limited's (HKG:8620) value has fallen 21% in the last week, but insiders who sold...

Potential Ruichang International Holdings Limited ( HKG:1334 ) shareholders may wish to note that the CEO, Interim...

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

We wouldn't blame Ximei Resources Holding Limited ( HKG:9936 ) shareholders if they were a little worried about the...

Viewing insider transactions for Ascletis Pharma Inc.'s ( HKG:1672 ) over the last year, we see that insiders were net...

Viewing insider transactions for BOSA Technology Holdings Limited's ( HKG:8140 ) over the last year, we see that...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Simcere...

Readers hoping to buy Wing On Company International Limited ( HKG:289 ) for its dividend will need to make their move...

Event driven spotlight on New World Development Recent discussion around New World Development (SEHK:17) has intensified as the stock trades at a discount to some intrinsic value estimates, while asset disposals and softer rental income keep investors focused on long term profitability. See our latest analysis for New World Development. Short term momentum has cooled, with the stock posting a 30 day share price return of down 18.82% and a 90 day share price return of down 18.03%, even though...

Dividend approval puts Uni-President China Holdings (SEHK:220) in focus Uni-President China Holdings (SEHK:220) has drawn investor attention after its annual general meeting approved a final dividend of 47.47 RMB cents per share for the 2025 financial year. The payout goes to shareholders on the register as of 15 June 2026. Dividend cheques are expected to be mailed on or around 8 July 2026, providing investors with clearer information on upcoming cash returns. See our latest analysis for...

REPT BATTERO Energy (SEHK:666) is back in focus after unveiling two new battery cells: a high capacity sodium ion product for large energy storage projects and a high power lithium ion cell tailored to AI data centers. See our latest analysis for REPT BATTERO Energy. The new battery launches come after a mixed run for REPT BATTERO Energy, with the latest HK$13.3 share price sitting alongside a 1-year total shareholder return of 18.33%, while the share price return has softened over the past...

Pop Mart International Group (SEHK:9992) is back in focus after management stressed that overseas growth is not solely tied to Labubu, even as the company presses ahead with more than 100 planned U.S. stores and a Labubu film collaboration. See our latest analysis for Pop Mart International Group. The recent focus on U.S. expansion and the Labubu film tie up comes after a period where the share price has been under pressure, with the 1 year total shareholder return down 31.68% even as the 3...

Prada (SEHK:1913) has partnered with Axiom Space to design astronaut garments for NASA's upcoming lunar missions. The luxury group will focus on inner-layer garments for future moon missions, extending its design expertise into space-focused technical wear. For investors tracking Prada at a current share price of HK$40.58, this move sits alongside a mixed return profile. The stock is up 10.5% over the past week and 13.0% over the past month, while returns over the past year and longer...

BYD (SEHK:1211) plans to start vehicle production at its new Hungary plant in Q4 2026, its first manufacturing facility in Europe. The company has paused plans for a separate factory in Turkey, indicating a change in how it is approaching European expansion. Local production in Hungary is intended to help address EU tariffs on Chinese-made electric vehicles. BYD, listed in Hong Kong under ticker SEHK:1211, is one of the largest electric vehicle and battery producers globally, with a growing...

HSBC’s latest Asia emerging markets report has put China Resources Land (SEHK:1109) on investors’ radar after highlighting expected margin improvement and upcoming flagship launches in Shanghai and Shenzhen. See our latest analysis for China Resources Land. At a share price of HK$37.28, China Resources Land has seen short term momentum cool slightly with a 1 month share price return that declined 2.41%. However, the 90 day share price return of 23.94% and 1 year total shareholder return of...

Chow Tai Fook Jewellery Group (SEHK:1929) just posted its FY 2026 results with second half revenue of HK$55.4b and basic EPS of HK$0.66, capping a year in which earnings grew 52.2% and net margin reached 9.5%. Over the past few reporting periods, revenue has moved from HK$50.2b in 2H FY 2025 to HK$38.0b in 1H FY 2026 and then to HK$55.4b in 2H FY 2026, while basic EPS shifted from HK$0.34 to HK$0.26 and then to HK$0.66. This progression gives investors a clearer view of how profitability is...

Fresh from releasing its FY 2026 numbers, Eagle Nice (International) Holdings (SEHK:2368) reported first half revenue of HK$3.3 billion and basic EPS of HK$0.36, with trailing twelve month revenue at HK$5.1 billion and basic EPS at HK$0.30. Over the past three reported half year periods, revenue has moved from HK$3.0 billion in 1H FY 2025 to HK$1.8 billion in 2H FY 2025 and HK$3.3 billion in 1H FY 2026, while basic EPS shifted from HK$0.33 to HK$0.06 and then HK$0.36, setting up a mixed...

In June, Everest Medicines (SEHK:1952) signed a global out licensing deal with Travere Therapeutics for its BTK inhibitor civorebrutinib (EVER001). The company also agreed to acquire presbyopia therapy LNZ100 from Corxel Pharmaceuticals and secured a regional cardiovascular licensing partnership for Sumecigrel from Jiangsu Vcare PharmaTech. Together, these transactions expand Everest Medicines' pipeline in nephrology, ophthalmology and cardiovascular disease while widening its collaboration...

Event overview and immediate market reaction LongBio Pharma (Suzhou) (SEHK:1779) moved higher in the latest session, with the stock closing at HK$141.9 after a 3.2% gain for the day, drawing fresh attention from biotech focused investors. See our latest analysis for LongBio Pharma (Suzhou). The 3.2% one day share price return fits into a year to date share price return of 7.66%. This suggests momentum has been gradually building as investors reassess LongBio Pharma (Suzhou)'s risk and growth...